The main category of All News Articles.
You can use the search box below to find what you need.
[wd_asp id=1]
The main category of All News Articles.
You can use the search box below to find what you need.
[wd_asp id=1]
XRP is drawing renewed market attention as a combination of technical patterns and macroeconomic developments may set the stage for a potential rally toward $1.90 in early 2026.
The digital asset has been consolidating near $1.84–$1.86 after months of sideways trading, forming a falling wedge pattern. This formation often precedes bullish reversals, but crypto’s volatility means confirmation is critical. Coupled with recent Federal Reserve liquidity injections, analysts suggest conditions may be favorable for a short-term upward move, if key support levels hold.
As of January 1, 2026, XRP is trading at $1.859, up 0.50% over 24 hours, with a trading volume of 1.77 billion XRP. Moderate volume suggests measured accumulation rather than aggressive buying, while the ongoing SEC lawsuit against Ripple, filed in 2020, continues to influence market sentiment and price volatility. TradingView analyst Leo524 noted that XRP has been in a strong downtrend over the past five months, repeatedly rejecting the descending trendline, and currently sits near a major green support zone, historically a launchpad for recovery moves.
XRP tests a key support zone after months of downtrend, with a potential recovery move if it breaks above the descending trendline. Source: Leo524 via X
“If the support zone holds and XRP breaks above the descending trendline, we can expect a potential recovery move,” Leo524 said.
From a technical perspective, traders should watch for a daily close above the descending trendline (~$1.88) with above-average volume as the first confirmation signal, while a breach of the $1.82–$1.84 support zone would weaken the bullish thesis. Broader market catalysts, including Bitcoin’s performance and institutional inflows, will also play a role. If conditions align, a move toward $1.90 becomes plausible, though it remains contingent on confirmation signals rather than guaranteed.
CRYPTO CAPTAIN (@UniverseTwenty) highlighted XRP’s daily chart, noting the classic falling wedge pattern: “The XRP breakout is imminent from this falling wedge pattern,” the analyst stated.

XRP gears up for a bullish surge as the falling wedge pattern signals a potential breakout toward $1.90. Source: @UniverseTwenty via X
On the daily chart, the wedge apex converges with the $1.82–$1.84 demand zone, which acts as a practical invalidation level. A daily close below this range would weaken the bullish thesis and signal that the pattern has failed.
Historical studies, including Bulkowski’s Encyclopedia of Chart Patterns, report a 68–74% success rate for falling wedges in equity markets. However, crypto markets are generally more volatile and leverage-driven, making pattern reliability more variable. In this context, analysts emphasize the need for volume confirmation to validate the breakout.
A key macro factor is the $74.6 billion repo injection by the Federal Reserve on December 31, 2025. X Finance Bull (@Xfinancebull) suggested this could benefit XRP and crypto more broadly, noting that liquidity is entering markets with tangible utility: “XRP has clarity, rails, and a fixed supply. Fiat expands. XRP doesn’t. That’s how this ends,” the analyst on X.

Fed pumps $74.6B liquidity, boosting XRP as smart capital flows into crypto with real utility and XRP’s fixed supply standing out. Source: @Xfinancebull via X
While increased liquidity may encourage investment in risk assets, it is important to distinguish correlation from causation. Historically, Fed repo operations primarily stabilize short-term money markets; their direct impact on XRP depends on risk-on sentiment and institutional flows.
Institutional adoption trends, such as the 2025 crypto ETF boom and the launch of Ripple’s RLUSD stablecoin, also provide potential support for XRP. Experts like Lyn Alden note that the record repo usage was a year-end balance sheet adjustment, not a financial crisis, which tempers expectations for guaranteed price jumps.
XRP’s setup combines technical patterns with macro liquidity support, pointing to a cautiously optimistic near-term scenario toward $1.90. The falling wedge indicates weakening selling pressure, and institutional interest alongside Fed liquidity provides potential upside.

XRP was trading at around 1.85, up 0.50% in the last 24 hours at press time. Source: XRP price via Brave New Coin
Traders should monitor the $1.82–$1.84 support zone, a trendline breakout around $1.88, and volume confirmation as key signals. Failure to hold these levels would delay or invalidate the bullish scenario. Despite SEC uncertainties, XRP’s utility, fixed supply, and growing adoption continue to support its potential, making $1.90 plausible, but not guaranteed.
Brent crude is expected to slide toward $55 a barrel in early 2026 as analysts warn that supply will outpace demand after oil posted its steepest annual fall since 2020.
The forecast matters as governments and central banks start the year watching energy costs for inflation, while producers weigh drilling plans and hedging strategies for 2026.
Traders are also looking to OPEC+ for direction ahead of a January 4 meeting, with the group’s next policy move seen as pivotal if prices drift into the low $50s.
Brent futures settled at $60.85 a barrel on Dec. 31, while U.S. West Texas Intermediate (WTI) ended at $57.42. Brent fell about 19% in 2025 and WTI nearly 20%, extending a multi-year losing streak for benchmarks.
BNP Paribas commodities analyst Jason Ying expects Brent to dip to $55 in the first quarter before recovering to $60 for the rest of 2026. “We think U.S. shale producers were able to hedge at high levels,” Ying said, referring to using derivatives to lock in future selling prices and keep production steady even if spot prices fall. Reuters
Morgan Stanley’s global oil strategist Martijn Rats said OPEC+ would likely respond with cuts only if prices fall substantially further, pointing to the low $50s as the area that could force the group’s hand, according to Reuters.
Most analysts expect a 2026 surplus, with estimates ranging from the International Energy Agency’s 3.84 million barrels per day to Goldman Sachs’ 2 million bpd. A surplus means the world is pumping more oil each day than it consumes, swelling inventories and weighing on prices.
OPEC+, which groups the Organization of the Petroleum Exporting Countries and allies including Russia, paused output hikes for the first quarter of 2026 after releasing about 2.9 million bpd into the market since April, Reuters reported.
U.S. data have also reinforced the market’s focus on demand. The Energy Information Administration said crude stockpiles fell by 1.9 million barrels in the week ended Dec. 26, while gasoline rose by 5.8 million barrels and distillates, including diesel and heating oil, climbed by 5 million barrels on strong refining runs. ( Reuters)
In the same report, “total product supplied” — a widely watched proxy for demand — dropped by 934,000 bpd to 19.38 million bpd, a decline that can signal softer consumption as the holiday period fades.
Geopolitics remains the wild card, analysts said, even with the market leaning bearish on fundamentals. The United States imposed new sanctions on four companies it said were operating in Venezuela’s oil sector and targeted associated tankers, a move Washington said was part of an intensified pressure campaign on President Nicolas Maduro. ( Reuters)
The U.S. action followed a broader push against what officials call a “shadow fleet” — older ships with opaque ownership and limited insurance that transport sanctioned oil — and came after a U.S. blockade announced earlier in December that Reuters said helped cut Venezuela’s exports to about half of November levels.
For now, the tug-of-war is clear: surging supply expectations and swelling inventories point lower, while OPEC+ policy and sanctions-driven disruptions could keep a floor under prices.
The next test comes quickly. Traders will watch the Jan. 4 OPEC+ meeting and early-2026 demand signals for clues on whether Brent stabilizes near $60 — or slips toward the mid-$50s that some banks have penciled in.
ELSEWHERE ON THE internet, you’re going to see a whole lot of nonsense about supplements.
You might hear—either from so-called “experts” or from supplement companies themselves—that certain pills or powders can help prevent and treat disease. You might read that supplements can dramatically change how you look and feel. You might even witness that certain products have the ability to detox your body from harmful environmental toxins.
If all of this sounds too good to be true, that’s because it largely is. We know this because for close to four decades, Men’s Health has tracked the scientific research and spoken with trusted authorities in the dietary supplement space.
We’ve taken all that scientific research and those conversations with credentialed experts and built the ultimate guide to supplement buying.
Download the Ultimate Supplement Guide
In this definitive Men’s Health guide you’ll find:
In short, if you’ve ever had a question about a supplement, you’re almost guaranteed you’ll find an answer to it in this guide.
Without this information, know that there’s one big thing you should watch out for: lack of oversight.
Supplement manufacturers can get away with making claims about what’s in their products and what they can do for you, health-wise, because they don’t have provide evidence to any governing body. In the United States, the FDA can ban ingredients, issue recalls for supplements already on the market, and send warning letters to supplement companies, but the agency largely does not regulate supplements before they go on sale.
That leaves you, as a consumer, to figure out if a product is safe and effective. And if that feels overwhelming, we got you.
MEN’S HEALTH MVP is a community of guys who are passionate about building their physical, mental, and emotional fitness, just as you are. And our MH MVP program is about giving you as many tools as possible to make that possible. This Hypertrophy program is just one of the vast array of features available that’ll help you become your best self.
Paul Kita is a Deputy Editor at Men’s Health, where he has covered food, cooking, nutrition, supplements, grooming, tech, travel, and fatherhood at the brand for more than 15 years. He is also the author of two Men’s Health cookbooks, Guy Gourmet and A Man, A Pan, A Plan, and the winner of a James Beard Award.
A price explosion of Bitcoin (BTC) to $250,000 in the year 2026 may lift the overall market, with established as well as new cryptos touching new heights. Top cryptos such as XRP will be on a winning streak with the institutional approach and developments in the payments sector. But it may be the new cheap crypto coin Mutuum Finance with a price of $0.04 that may attract attention.
In the event that the price of Bitcoin (BTC) is set to have a price cycle top at $250,000, there might be an increase in the price of XRP as well. Although the year 2025 has turned out very badly for the whole altcoin market, as it has fallen as low as 42% in value, it is very interesting that the price of XRP has fallen merely by 15%. This is in line with the fast expansion that Ripple is making, which includes more than $2.7 billion worth of acquisitions in payments, treasury management software and trading infrastructure.
Another factor which has worked in favor of XRP is the improvement in the regulatory environment, where Ripple has finally closed its case in the SEC after a couple of years, paving the way for new investments. If a price rise is to happen, then it is likely that the defensive holding qualities of XRP, along with the resilience it has shown in the past, may help it to deliver huge profits. However, XRP is unlikely to be the next big crypto. Factors such as its large market cap could lead to minimal growth. On the other hand, Mutuum Finance could easily shock the market with its upside.
Mutuum Finance (MUTM) has now launched Phase 7 of its presale, and token prices are set at $0.04. It follows Phase 6, where the token was set at $0.035, an increase of 15%. The project has shown incredible momentum, and analysts see the token breaking past its $0.06 market debut price in no time.
If Bitcoin hits $250,000 in the next bull run, Mutuum Finance could soar as high as 50x from its current price to hit $2. This will position MUTM as one of the best performing DeFi cryptos in the 2026 bull run. In addition, an investment of just $100 at today’s price will balloon to $5000 if this rally materializes.

Since the presale began, more than 18,630 investors have participated, and over $19.5 million of funding has been raised. The dual nature of the token, together with the soon-to-be-launched V1 Sepolia Testnet, continues to attract investors, as there is genuine utility in play. MUTM has been audited by Certik, where the project emerged with a 90/100 token scan score, showing it’s a safe investment opportunity. White hackers can also participate in a $50,000 bug bounty program to identify possible vulnerabilities in the project. These measures show how seriously the team behind Mutuum Finance takes security. As a result, smart money investors recognize MUTM as a high-potential crypto to buy now.
An important aspect of Mutuum Finance is its mtToken system, which rewards individuals who bring assets to lend to the platform. While traditional assets only generate interest when they are withdrawn, mtTokens provide investors with the opportunity to generate passive income in real-time while still enjoying liquidity. This is an innovative platform that improves MUTM’s usable utility in the marketplace and solidifies it as the most promising cheap crypto coin to invest in 2026.
Aside from an audit by CertiK, Halborn Security has also conducted an independent audit of MUTM, concentrating on its lending and borrowing contracts. The MUTM team has integrated the audit’s feedback and is now preparing for Sepolia testnet debut. The tesnet will mark the project’s first public deployment. This version will introduce core components including:
Initially, the protocol will support ETH and USDT as primary assets for lending, borrowing, and collateral. The testnet launch allows users and users to interact with the platform, provide feedback, and help optimize the system before mainnet release.
If Bitcoin (BTC) reaches $250,000 in 2026, both XRP and Mutuum Finance are primed for rallies. However, while XRP’s upside could easily be limited by its large market cap, MUTM shows potential for up to 50x returns. With a cost of just $0.04 in Phase 7, MUTM already boasts over $19.5M in funds raised in its fast-growing presale. This makes MUTM not only a crypto to buy now but a no-brainer pick over XRP.
For more information about Mutuum Finance (MUTM) visit the links below:
Website: https://mutuum.com/
Linktree: https://linktr.ee/mutuumfinance
NEW YORK, January 1, 2026, 13:00 ET — Market closed
The United States Natural Gas Fund (UNG) sank 6.7% on Wednesday, the last U.S. trading session of 2025, tracking a sharp pullback in U.S. natural gas prices after traders leaned into a warmer weather outlook for early January.
The move matters because winter pricing is still dominated by short-term swings in heating demand, and forecasts can change quickly. A warmer-than-normal pattern typically means less gas burned for heat and fewer withdrawals from storage.
It also lands as U.S. liquefied natural gas (LNG) exports keep running at high levels, tying domestic prices more closely to export demand. That support can be offset in the near term when weather turns milder and production stays high.
UNG closed at $12.26, after trading between $12.18 and $12.69 during the session.
Among gas-heavy producers, EQT fell 1.9%, Antero Resources slid 1.8% and Range Resources dropped 2.3%. LNG exporter Cheniere Energy rose 0.5%.
In the futures market, front-month February Henry Hub contracts were down 5.7% at $3.745 per million British thermal units by 12:41 p.m. ET on Wednesday, pressured by warmer forecasts for next week and a smaller-than-expected storage withdrawal, even as record gas flows to LNG export facilities in 2025 kept the market on track for a second straight annual gain. BOE Report
Meteorologists projected above-normal temperatures across the country through Jan. 14, Reuters reported, and Heating Degree Days — a measure of energy demand to heat buildings — fell to 413 from 439 a day earlier. BOE Report
The Energy Information Administration said utilities withdrew 38 billion cubic feet (bcf) from storage for the week ended Dec. 26. One bcf is a billion cubic feet of gas. BOE Report+1
Working gas in storage stood at 3,375 bcf, the EIA data showed. That left inventories about 58 bcf above the five-year average for this time of year, based on the agency’s historical comparisons. EIA Information Releases
On the supply side, LSEG data showed Lower 48 output averaging 110.1 billion cubic feet per day (bcfd) in December, a record, while average feedgas deliveries to the eight big U.S. LNG export plants reached 18.5 bcfd in December. Feedgas is gas delivered to liquefaction terminals for export. BOE Report
“Given this weather and the drawdown number, there’s really not a whole lot of room for the natural gas prices to go up,” said Zhen Zhu, a managing consultant at C.H. Guernsey and Company in Oklahoma City. BOE Report
Before the next session: U.S. markets reopen on Jan. 2, and traders are likely to keep treating weather model shifts and LNG feedgas flows as the main near-term catalysts. The next weekly storage report from the EIA is scheduled for Jan. 8, following Wednesday’s holiday-shifted release. EIA Information Releases+2EIA Information Releases+2
UNG’s Wednesday low of $12.18 is the first level many short-term traders will watch for signs of another wave of selling, while the day’s high of $12.69 marks the nearby upside hurdle if gas prices rebound.
Bitcoin’s current price has traders talking as it sits at $87,497.94, showing a slight decline of 1.03%. With an RSI of 42.63 signaling potential future movements, investors are speculating whether BTCUSD can reach its forecasted target of $91,771. Let’s dive into the technical indicators and market trends to understand what’s driving Bitcoin’s fluctuations.
As of now, Bitcoin is priced at $87,497.94, down 1.03% from its previous close of $88,407.73. Volume is significantly lower at 760,042,936 compared to the average of 63,741,527,337. These figures suggest a pause in trading momentum, reflected in the daily low of $87,082.64 and a high of $89,100.00. The market cap stands firm at approximately $1.7 trillion, indicating Bitcoin’s resilience amid volatility.
The RSI at 42.63 suggests that the market isn’t heavily overbought or oversold, leaving room for potential upward movement. The MACD stands at -1,943.84, with a histogram of 440.83, indicating a bearish sentiment that might be shifting. ADX is strong at 31.67, showing a solid trend, which could be pivotal for market direction in the coming weeks.
Forecasts predict Bitcoin could hit $91,771 this month, supported by technical patterns and market sentiment. The quarterly projection is even higher at $137,052.42, while yearly expectations predict a mild dip to $83,932.49. These forecasts reflect Bitcoin’s potential to overcome short-term setbacks, as historical resilience shows in its three-year growth of 517.94%. Forecasts can change due to macroeconomic shifts, regulations, or unexpected events affecting the crypto market.
Recent news highlights Bitcoin’s evolving role in financial markets. While no major news events have dramatically shifted prices in the last 24 hours, consistent attention from finance platforms underscores Bitcoin’s relevance. This coverage helps maintain trader interest and can subtly impact sentiment, influencing trading volumes and price movements. As Meyka AI suggests, keeping an eye on such developments is crucial for informed trading decisions.
Bitcoin’s price fluctuations underline the complexity of crypto markets, where a multitude of factors can shift sentiment and direction. With predictions aiming for $91,771, traders should remain alert to indicators and news that could influence the landscape. Continual analysis and adaptation will be key as forecasts evolve.
As of the latest data, BTCUSD is priced at $87,497.94, reflecting a 1.03% decrease from the previous close of $88,407.73. For more detailed updates, visit this BTCUSD page.
The RSI is at 42.63, suggesting Bitcoin is neither overbought nor oversold, which may indicate potential upward movement depending on market conditions.
Bitcoin is forecasted to reach $91,771 this month and $137,052.42 quarterly, with a potential yearly dip to $83,932.49. Long-term predictions include $108,532.96 over three years.
The current volume of 760,042,936 is below the average, indicating reduced trading activity, which can contribute to price stabilization or minor fluctuations.
Forecasts can change due to macroeconomic shifts, regulations, or unexpected events affecting the crypto market, impacting sentiment and price direction.
Disclaimer:
Cryptocurrency markets are highly volatile. This content is for informational purposes only.
The Forecast Prediction Model is provided for informational purposes only and should not be considered financial advice.
Meyka AI PTY LTD provides market data and sentiment analysis, not financial advice.
Always do your own research and consider consulting a licensed financial advisor before making investment decisions.
In this feature article from our April issue of Nutritional Outlook, neurologist Alexander Zubkov presents an integrative approach to long-term cognitive health, focusing on the most studied nutrients and herbs for brain health, when to start taking supplements, and the role of gut-brain connection.
“We now understand that brain health is deeply connected to what we consume,” Zubkov explains. “The neurons in our brain rely on a steady supply of essential nutrients, healthy fats, and antioxidants to function optimally. Deficiencies in key vitamins and minerals—such as B vitamins, magnesium, and omega-3 fatty acids—can impair neurotransmitter production and accelerate cognitive decline.”
He adds, “For those looking to maintain optimal cognitive health, the key is proactive maintenance. Whether through dietary changes, targeted supplementation, or lifestyle modifications, we all have the power to influence our brain’s longevity. And in the evolving field of neurology, I believe that embracing an integrative mindset will be the future of brain health care.”
Here, David DeSouza, president of Monterey Bay Herb Co., highlights popular nootropic herbs and strategies for formulating high quality and effective products that responsibly communicate benefits in line with federal regulations. He explains the leading botanicals in the category, sourcing and efficiency, and responsible marketing strategies.
“The rise of botanical nootropics signals a broader shift in how consumers approach mental performance,” he explains. “As the brain health category expands, natural ingredients offer a compelling foundation for products that align with both wellness goals and clean-label values. However, successful innovation depends on more than ingredient choice. Brands that commit to clinical rigor, responsible sourcing, and ethical storytelling will be best positioned to lead—and sustain—growth in the cognitive health space.”
In this article, the Cognitive Health Committee of the Institute for the Advancement of Food and Nutrition Sciences (IAFNS) explores the significant gap in knowledge about the impact nutrition has on adolescent cognitive development.
To highlight opportunities to learn more about the impact of nutrition during adolescence, the IAFNS committee initiated a systematic review, led by researchers at Swansea University, focused on a comprehensive age range of 8 to 19 years, author Marie Latulippe, MS, MBA, RDN explains. In total, 48 randomized controlled trials and 25 prospective cohort studies met the inclusion criteria. Because of lack of consistency across studies, it was difficult to discern the impacts of specific nutrients on cognition and academic achievement. There were beneficial effects for some nutrients such as Vitamin D, choline, polyphenols, and whole grains, but evidence was sparse. Although conclusions were elusive, this review points to a significant gap in knowledge about how nutrition can be impactful in adolescence.
In our January/February issue of Nutritional Outlook, Editor Madeline Colli explains how vitamin B12 is gaining steam in the cognitive health category and proving to be a supplement to watch. Colli spotlights the core mechanisms of the vitamin, consumer interest, the variety of its forms, and its growth in the market.
“The importance of vitamin B12 for human health, particularly cognitive health, is well established,” Colli explains. “Naturally, vitamin B12 is a valuable addition to these formulas as manufacturers combine herbs and proprietary ingredients with tried and true vitamins and minerals that speak to a basic understanding of nutrition.”
In our March issue of Nutritional Outlook, Editor Sebastian Krawiec explores the role of nutrition in reducing the risk of age-related cognitive impairment, and why more research is necessary to validate claims and promote innovation, referencing multiple published research studies.
“Confidence in supplements and their cognitive health claims varies, with most medical professionals not putting much stock in them largely due to the lack of large clinical trial data validating these benefits,” Krawiec explains. “Many take issue with what they view as deceptive and predatory marketing since people already experiencing cognitive deficits are unlikely to see any measurable improvements. That is not to say that certain nutrients and herbs cannot support cognitive health, simply that more substantiation is required.”
Felix Pinkston
Jan 01, 2026 11:42
MATIC price prediction shows potential for 18-37% gains to $0.45-$0.52 range within 4-6 weeks, contingent on breaking critical $0.58 resistance level amid neutral RSI conditions.
Polygon’s native token MATIC is positioned at a critical juncture as we enter 2026, trading at $0.38 with technical indicators presenting a mixed but cautiously optimistic outlook. Our comprehensive MATIC price prediction analysis reveals potential for significant upside movement, though key resistance levels must be conquered first.
• MATIC short-term target (1 week): $0.42 (+10.5%)
• Polygon medium-term forecast (1 month): $0.45-$0.52 range (+18% to +37%)
• Key level to break for bullish continuation: $0.58
• Critical support if bearish: $0.35-$0.33
The latest analyst sentiment shows a cautious but optimistic Polygon forecast consensus. Blockchain.News presents the most bullish MATIC price prediction with targets of $0.45-$0.52 in the medium term, emphasizing the critical importance of breaking the $0.58 resistance barrier. This aligns with our technical analysis showing this level as the primary obstacle to bullish continuation.
CoinCodex’s AI-driven model offers a more conservative short-term MATIC price target of $0.1040, suggesting minimal movement, while Coinbase projects a modest long-term target of $0.13 over five years. The divergence in these predictions reflects the current uncertainty in MATIC’s direction, with most analysts agreeing that breaking key resistance levels will be crucial for confirming any bullish momentum.
Current Polygon technical analysis reveals MATIC trading below all major moving averages except the 7-day SMA ($0.37), indicating the token is still in a corrective phase. The price sits at $0.38, positioned at the daily pivot point, suggesting a critical decision zone.
The RSI reading of 38.00 places MATIC in neutral territory with room for upward movement without reaching overbought conditions. However, the MACD histogram at -0.0045 shows bearish momentum persists, though the relatively small magnitude suggests this bearish pressure may be weakening.
Volume analysis shows moderate trading activity at $1,074,371 on Binance spot, which needs to increase significantly to support any meaningful price breakout. The Bollinger Bands position at 0.29 indicates MATIC is trading in the lower portion of its recent range, potentially setting up for a mean reversion trade.
Our bullish MATIC price prediction scenario targets the $0.45-$0.52 range within 4-6 weeks. This represents the convergence zone of the 50-day SMA ($0.45) and the upper Bollinger Band resistance around $0.52.
For this bullish case to materialize, MATIC must first reclaim the 20-day EMA at $0.42, then challenge the critical $0.58 resistance level. A decisive break above $0.58 would likely trigger momentum buying, potentially pushing MATIC toward the $0.65-$0.70 zone where the 200-day SMA currently resides.
Key catalysts supporting this Polygon forecast include potential network upgrades, increased DeFi activity, and broader cryptocurrency market recovery. The technical setup suggests MATIC has established a base around current levels, with the 52-week low of $0.37 providing strong psychological support.
The bearish scenario for our MATIC price prediction involves a breakdown below the immediate support at $0.35, which could trigger selling pressure toward the strong support zone at $0.33. This level represents both a technical support confluence and proximity to the 52-week low.
Risk factors include continued bearish MACD momentum, failure to reclaim moving average resistance levels, and potential broader market weakness. A break below $0.33 could signal a more prolonged correction, potentially testing the $0.28-$0.30 zone.
Based on our Polygon technical analysis, the current risk-reward setup presents mixed signals. Conservative buyers should wait for a clear break above $0.42 (20-day EMA) before initiating positions, with a MATIC price target of $0.45-$0.52.
Aggressive traders might consider accumulating near current levels ($0.38) with strict stop-losses below $0.35. The key question of “buy or sell MATIC” depends on risk tolerance, but the technical setup suggests more upside potential than downside risk at current levels.
Position sizing should remain conservative given the bearish MACD momentum, with maximum 2-3% portfolio allocation recommended. Stop-loss levels should be placed below $0.35 for long positions, representing approximately 8% downside risk from current levels.
Our comprehensive MATIC price prediction forecasts a potential 18-37% upside move to the $0.45-$0.52 range over the next 4-6 weeks, contingent on breaking the critical $0.58 resistance level. The confluence of analyst targets and technical indicators supports this Polygon forecast, though execution remains dependent on broader market conditions.
Confidence Level: Medium (65%)
Key indicators to monitor for confirmation include MACD turning positive, RSI breaking above 45, and volume expansion on any upward moves. Invalidation of this bullish MATIC price prediction would occur on a decisive break below $0.35, potentially triggering deeper correction toward $0.33 support.
Timeline for this prediction spans 4-6 weeks, with the first major test occurring at the $0.42 resistance level within the next 7-10 days.
Image source: Shutterstock
Morgan Stanley presents the most bullish scenario, projecting GBP/USD at 1.47 by end-2026, with upside extensions toward 1.50 if US growth decelerates sharply. Their base case assumes three additional Fed cuts in the first half of 2026, driving the fed funds rate toward 3.00% and compressing US rate differentials. Still, even Morgan Stanley has moderated its earlier conviction, acknowledging that dollar weakness may prove more measured and front-loaded.
MUFG adopts a middle-ground approach, projecting GBP/USD near 1.40 by mid-2026, consistent with a gradual rather than disorderly dollar decline. Importantly, MUFG has revised forecasts higher for the dollar relative to earlier expectations, reflecting its resilience despite easing.
If the Fed sets the ceiling for GBP/USD, the Bank of England likely defines the floor. After cutting rates five times in 2025, bringing Bank Rate to 4.00%, markets expect further easing. Consensus forecasts see rates falling to 3.25% by Q3 2026, with several institutions calling for 3.00% or lower by year-end.
The rationale is straightforward. UK growth remains weak, GDP contracted in October 2025, and unemployment has risen to 5.0%. At the same time, inflation remains elevated at 3.6%, leaving the BoE balancing fragile growth against incomplete disinflation. Morgan Stanley expects rates as low as 2.75%, a move that would materially erode Sterling’s carry support.
This aggressive easing bias limits Sterling’s ability to outperform, even in a weakening dollar environment. Unlike earlier cycles, GBP’s upside is unlikely to be driven by yield differentials and instead relies on relative economic resilience and capital flows.
Upside risks for GBP/USD are overwhelmingly dollar-centric. A sharper-than-expected US slowdown could force the Fed into faster or deeper cuts, pushing GBP/USD toward the upper end of forecasts. Similarly, a policy misstep that tightens financial conditions into labor market weakness would likely weigh on the dollar.
Sterling-specific upside is harder to justify but not impossible. A stabilization in UK growth, improved productivity trends, or credible fiscal signaling could help GBP outperform expectations, though these remain secondary drivers.
Downside risks remain meaningful. Sticky US inflation could stall Fed easing and preserve dollar yield support. In the UK, fiscal scrutiny is likely to intensify ahead of future budget cycles, particularly if debt dynamics worsen. A global risk-off episode would also favor the dollar, regardless of valuation arguments.
From a technical standpoint, GBP/USD faces heavy resistance in the 1.38–1.42 zone, an area that capped rallies in prior cycles. Support near 1.30–1.32 has held consistently, suggesting a broad trading range rather than a trending market.
Positioning remains elevated following Sterling’s 2025 performance, increasing vulnerability to pullbacks if underlying momentum fades. Sustained breaks above 1.38 would likely require either pronounced US weakness or a material improvement in UK fundamentals, neither of which sits in the consensus base case.
In recent years, the quest for effective treatments and supplements that can aid cognitive function has captured the attention of both researchers and healthcare enthusiasts. The exploration of natural compounds continues to hold promise, with various dietary supplements emerging for their potential neuroprotective properties. A groundbreaking study has been conducted by a team of scientists, including Aboubaker, D.H., Elsayed, A.A.A., and El-Gohary, A., titled “Author Correction: Introduction of Cistanche phelypaea fatty acids as a new natural neurotrophic supplement by evaluating its effects in normal and Alzheimer’s diseased rats.” This significant research delves into the therapeutic potential of Cistanche phelypaea, an herb long recognized in traditional medicine, regarded for its supposed cognitive-enhancing properties.
Cistanche phelypaea, a member of the Orobanchaceae family, has garnered interest due to its unique bioactive compounds, particularly fatty acids, that are believed to play a crucial role in cellular health and cognitive function. The herb has been used in traditional Asian medicine, yet its systematic exploration within modern scientific contexts is still emerging. The current investigation evaluates how these fatty acids may function as neurotrophic supplements, providing the necessary support for neuronal health and regeneration.
Neurotrophic factors are essential for the growth, survival, and differentiation of neurons. They are critical players in the maintenance of brain health, and their deficiency is often linked to neurodegenerative diseases such as Alzheimer’s. In this study, the authors sought to determine whether Cistanche phelypaea could enhance the presence or activity of these neurotrophic factors, ultimately leading to improved cognitive function in both normal conditions and in the presence of Alzheimer’s pathology.
To conduct their research, the team utilized an animal model, deploying both healthy and Alzheimer’s diseased rats in a series of behavioral and biochemical assays. The choice of rats as their model organism allowed for sufficient ethical flexibility while providing reliable insights into mammalian biology. Through rigorous experimentation, they could glean data on how the administration of Cistanche phelypaea fatty acids influenced cognitive performance and neurochemical markers associated with brain health.
One of the standout results from this research was a marked improvement in cognitive performance among the rats that received the fatty acids. The researchers employed a series of mazes and memory tasks to assess the cognitive abilities of the subjects. Rats administered with Cistanche phelypaea showed enhanced memory recall and spatial navigation abilities compared to those in the control group. Such findings are critical as they suggest that the fatty acids could counteract cognitive decline, especially in the context of Alzheimer’s disease.
Biochemical analyses further substantiated the behavioral results. Blood samples and brain tissues were examined for changes in levels of neurotrophic factors such as Brain-Derived Neurotrophic Factor (BDNF), which is crucial for synaptic plasticity and overall brain function. The study reported elevated levels of BDNF in the brain tissues of treated rats, indicating that Cistanche phelypaea may indeed facilitate neuroprotection and neurogenesis. This biochemical support complements the observed behavioral improvement, suggesting a dual mechanism at play.
The implications of this study extend far beyond the laboratory. As the global population ages, the incidence of neurodegenerative diseases is projected to rise significantly. The quest for effective treatments has become an urgent priority on the public health front. The results from Aboubaker et al.’s research open new avenues for exploring natural therapies and encourage further investigation into plant-based compounds that can contribute positively to brain health.
Moreover, the research also highlights the importance of revisiting traditional herbal practices through the lens of modern science. Cistanche phelypaea’s long-standing use in traditional medicine can inform contemporary clinical applications, bridging the gap between ancient wisdom and scientific validation. This study thus not only reinforces the value of natural products but also emphasizes the need for rigorous scientific investigation into herbal medicine.
As the scientific community continues to investigate potential solutions to combat cognitive decline, this study serves as a beacon of hope. With natural neurotrophic supplements like Cistanche phelypaea gaining recognition, there may soon be viable alternatives to synthetic drugs that often come with a myriad of side effects. The positive results from this research underscore the necessity for continued exploration of botanical compounds that hold promise for brain health.
Furthermore, this exploration is particularly timely given the rising interest in personalized medicine and wellness. Many individuals are actively seeking natural supplements to improve their cognitive performance, enhance memory, or support overall brain health. As interest flourishes in this area, studies like this one contribute valuable knowledge that aids consumers in making informed choices about their health.
However, it is essential to approach this emerging field with a balanced perspective. While the potential benefits of Cistanche phelypaea are promising, there remains a need for thorough clinical trials in humans before establishing definitive efficacy and safety profiles. The research team acknowledges that more extensive studies are required to ascertain optimal dosages and long-term effects, ensuring that the transition from animal models to human applications is safely navigated.
In conclusion, the work of Aboubaker and colleagues represents a pivotal step in understanding the neuroprotective potential of Cistanche phelypaea fatty acids. Their findings not only enrich the existing literature on neurotrophic supplementation but also invigorate the discourse surrounding natural therapeutics in cognitive health. As research in this field progresses, there is hope that such natural compounds could become integral components of strategies aimed at mitigating the impact of neurodegenerative diseases and enhancing cognitive well-being.
While the present study is promising, it is crucial to keep in mind the broader context of brain health. Lifestyle factors such as diet, exercise, and mental stimulation consistently demonstrate their significance in supporting cognitive function. Integrating natural supplements with a holistic approach to brain health may provide the best outcomes for individuals looking to maintain cognitive vitality throughout their lives. Research like that conducted by Aboubaker et al. plays a vital role in directing attention to natural solutions, encouraging both scientific inquiry and public awareness of the potential benefits of herbal supplements.
Subject of Research: The effects of Cistanche phelypaea fatty acids as a natural neurotrophic supplement.
Article Title: Author Correction: Introduction of Cistanche phelypaea fatty acids as a new natural neurotrophic supplement by evaluating its effects in normal and Alzheimer’s diseased rats.
Article References:
Aboubaker, D.H., Elsayed, A.A.A., El-Gohary, A. et al. Author Correction: Introduction of Cistanche phelypaea fatty acids as a new natural neurotrophic supplement by evaluating its effects in normal and Alzheimer’s diseased rats. Sci Rep 15, 45801 (2025). https://doi.org/10.1038/s41598-025-34156-3
Image Credits: AI Generated
DOI: 10.1038/s41598-025-34156-3
Keywords: Cistanche phelypaea, fatty acids, neurotrophic supplement, Alzheimer’s disease, cognitive function.
Tags: Alzheimer’s disease treatment researchbioactive compounds for neuronal healthCistanche phelypaea fatty acidscognitive enhancement through supplementsdietary supplements for brain regenerationfatty acids and neuronal survivalnatural compounds for brain healthneuroprotective properties of herbal remediesneurotrophic supplements for cognitive functionOrobanchaceae family medicinal usestherapeutic potential of Cistanchetraditional medicine and modern science